In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) was $857.47K for the day, up 1284724% from the previous closing price of $1.38. In other words, the price has increased by $1284724 from its previous closing price. On the day, 1.28 million shares were traded. ZNTL stock price reached its highest trading level at $1.405 during the session, while it also had its lowest trading level at $1.245.
Ratios:
Our analysis of ZNTL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.94 and its Current Ratio is at 6.94. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.13.
On June 20, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $28 to $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 30 ’25 when Myers Scott Dunseth bought 21,000 shares for $1.40 per share. The transaction valued at 29,373 led to the insider holds 281,192 shares of the business.
Bruns Ingmar bought 20,000 shares of ZNTL for $45,656 on Feb 06 ’25. The Chief Medical Officer now owns 36,629 shares after completing the transaction at $2.28 per share. On Feb 11 ’25, another insider, Cam Gallagher, who serves as the Former Director of the company, bought 687 shares for $2.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZNTL now has a Market Capitalization of 93537472 and an Enterprise Value of -196755488. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.48 while its Price-to-Book (P/B) ratio in mrq is 0.32. Its current Enterprise Value per Revenue stands at -7.324 whereas that against EBITDA is 0.987.
Stock Price History:
The Beta on a monthly basis for ZNTL is 1.61, which has changed by -0.7173913 over the last 52 weeks, in comparison to a change of 0.09544468 over the same period for the S&P500. Over the past 52 weeks, ZNTL has reached a high of $5.70, while it has fallen to a 52-week low of $1.01. The 50-Day Moving Average of the stock is -2.69%, while the 200-Day Moving Average is calculated to be -46.44%.
Shares Statistics:
ZNTL traded an average of 857.47K shares per day over the past three months and 913880 shares per day over the past ten days. A total of 71.95M shares are outstanding, with a floating share count of 55.80M. Insiders hold about 22.44% of the company’s shares, while institutions hold 76.55% stake in the company. Shares short for ZNTL as of 1748563200 were 5879347 with a Short Ratio of 6.86, compared to 1745971200 on 5824182. Therefore, it implies a Short% of Shares Outstanding of 5879347 and a Short% of Float of 10.2.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
